HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Allergan

This article was originally published in The Rose Sheet

Executive Summary

Allergan: Confirms that it is in discussions regarding the "potential acquisition" of Herald Pharmacal, a Richmond, VA-based manufacturer and marketer of dermatological products. In a July 25 release, the company also said the Federal Trade Commission has granted early termination of the 60-day Hart-Scott-Rodino waiting period in connection with the possible merger. Herald's products are marketed primarily under the M.D. brand, sold through dermatologists and salons, and the Aqua Glycolic brand of glycolic acid-based products, sold through drug stores. The Allergan Herbert skin care division had sales of $37.3 mil. in 1994...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS001861

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel